Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.

Marrero DG, Crean J, Zhang B, Kellmeyer T, Gloster M, Herrmann K, Rubin R, Fineberg N, Kolterman O

Diabetes care1 Feb 2007Cited by 33 (Europe PMC)

PMID17259483DOI10.2337/dc06-1026PepBankPUB-17259483

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, pramlintide recipients reported greater treatment satisfaction in most questionnaire responses than placebo recipients.
In plain wordsIn patients with type 1 diabetes, treatment satisfaction was generally higher with pramlintide than placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseTreatment satisfaction
Study
n = 266
Comparator
Placebo
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 29 weeksAs given in this study (human).
Source sentences
Summary
Pramlintide-treated patients reported greater treatment satisfaction in most questionnaire responses.
1 context sentence(design, population, supporting numbers)
Summary · context
Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a do…
Report a problemFND-1725948301
02HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, A1C fell similarly with pramlintide and placebo.
In plain wordsIn patients with type 1 diabetes, A1C fell by a similar amount with pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeA1C change
Study
n = 266
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 29 weeksAs given in this study (human).
Measurements
A1C change
−0.39%
pramlintide
A1C change
−0.45%
placebo
Source sentences
Summary
Mean A1C was reduced to a similar degree in both pramlintide- (-0.39 +/- 0.07%) and placebo-treated (-0.45 +/- 0.07%) patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a do…
Report a problemFND-1725948303
03HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, pramlintide reduced weight while placebo recipients gained weight over 29 weeks.
In plain wordsIn patients with type 1 diabetes, weight fell with pramlintide but rose with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight change
Study
n = 266
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 29 weeksAs given in this study (human).
Measurements
Weight change
−1.5 kg
pramlintide
Weight change
1.28 kg
placebo
Source sentences
Summary
However, pramlintide treatment was associated with reductions in mean body weight (-1.50 +/- 0.33 kg; P < 0.0001) and mealtime insulin use (-19.05 +/- 5.17%; P < 0.005) over 29 weeks, while placebo treatment resulted in weight gain (1.28 +/- 0.25 kg) and a smaller reduction in mealtime insulin use (-2.20 +/- 3.33%).
1 context sentence(design, population, supporting numbers)
Summary · context
Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a do…
Report a problemFND-1725948304
04HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, mealtime insulin use declined more with pramlintide than placebo over 29 weeks.
In plain wordsIn patients with type 1 diabetes, insulin use at meals fell more with pramlintide than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMealtime insulin use
Study
n = 266
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 29 weeksAs given in this study (human).
Measurements
Mealtime insulin change
−19.05%
pramlintide
Mealtime insulin change
−2.2%
placebo
Source sentences
Summary
However, pramlintide treatment was associated with reductions in mean body weight (-1.50 +/- 0.33 kg; P < 0.0001) and mealtime insulin use (-19.05 +/- 5.17%; P < 0.005) over 29 weeks, while placebo treatment resulted in weight gain (1.28 +/- 0.25 kg) and a smaller reduction in mealtime insulin use (-2.20 +/- 3.33%).
1 context sentence(design, population, supporting numbers)
Summary · context
Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a do…
Report a problemFND-1725948305

Studies that did not test the peptide alone1

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

05HumanNot a test of Pramlintide (Symlin) aloneObservational studyEfficacy outcome
In pramlintide-treated patients with type 1 diabetes, treatment satisfaction was similar with multiple daily injections and insulin pump therapy.
In plain wordsIn pramlintide-treated patients with type 1 diabetes, satisfaction was similar with insulin injections and insulin pumps.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeTreatment satisfaction by insulin delivery regimen
Study
n = 130
Comparator
Multiple daily injections versus continuous subcutaneous insulin infusion
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Treatment satisfaction was similar for pramlintide-treated patients regardless of intensive insulin regimens (MDI versus CSII).
1 context sentence(design, population, supporting numbers)
Summary · context
Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a do…
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1725948302

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.